A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamos Non-Small Cell Lung Cancer That is Stage IIIB, Stage IV or Recurrent
A study for subjects with non-small cell lung cancer using study drug Ruxolitinib
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAN7916
U.S. Govt. ID: NCT02119650
Contact: Balazs Halmos: 212-305-5874 / bh2376@columbia.edu
Additional Study Information: The purpose of this study is to find out whether the drug, ruxolitinib, is effective, tolerable and safe in combination with two chemotherapy medicines called pemetrexed and cisplatin. The study will test if this combination has beneficial effects in people diagnosed with certain types of non-small cell lung cancer. Only participants with Stage IIIB, Stage IV or recurrent non-small cell lung cancer may participate.
This study is closed
Balazs Halmos, MD
Do You Qualify?
Do you have Stage IIIB, Stage IV or recurrent non small cell lung cancer? Yes No
Do currently suffer from any uncontrolled (untreated) cardiac disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Balazs Halmos